Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 13/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978168 | 0.85 | KDM4E (0.49) | HDAC3HDAC1HDAC6GRM5NPC1 | |
| SCHEMBL976807 | 0.85 | HDAC1 (0.47) | HDAC3HDAC1HDAC6GRM5NPC1 | |
| SCHEMBL10825415 | 0.83 | KMT2A (0.46) | HDAC3HDAC1HDAC6GRM5NPC1 | |
| SCHEMBL975949 | 0.79 | HDAC3 (0.43) | HDAC3HDAC1HDAC6 | |
| SCHEMBL10825512 | 0.79 | GAA (0.43) | HDAC3HDAC1HDAC6GRM5NPC1 | |
| SCHEMBL978811 | 0.78 | F10 (0.55) | HDAC3HDAC1HDAC6GRM5NPC1 | |
| SCHEMBL28895700 | 0.77 | GRM5 (0.44) | HDAC3HDAC1HDAC6GRM5NPC1 | |
| SCHEMBL979703 | 0.76 | HDAC1 (0.43) | HDAC3HDAC1HDAC6 | |
| SCHEMBL978489 | 0.75 | F10 (0.43) | HDAC3HDAC1HDAC6ALDH1A1 | |
| SCHEMBL980083 | 0.74 | GRM5 (0.50) | HDAC3HDAC1HDAC6GRM5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440830-B2 | Tetrahydro-fused pyridines as histone deacetylase inhibitors | 4SC AG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC3 | HDAC3 3/4885HDAC1 1/4885HDAC6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.